480 related articles for article (PubMed ID: 32061923)
21. Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Baggio LL; Varin EM; Koehler JA; Cao X; Lokhnygina Y; Stevens SR; Holman RR; Drucker DJ
Nat Commun; 2020 Jul; 11(1):3766. PubMed ID: 32724076
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic vaccine against DPP4 improves glucose metabolism in mice.
Pang Z; Nakagami H; Osako MK; Koriyama H; Nakagami F; Tomioka H; Shimamura M; Kurinami H; Takami Y; Morishita R; Rakugi H
Proc Natl Acad Sci U S A; 2014 Apr; 111(13):E1256-63. PubMed ID: 24639549
[TBL] [Abstract][Full Text] [Related]
23. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.
Wagner L; Klemann C; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jun; 184(3):265-83. PubMed ID: 26671446
[TBL] [Abstract][Full Text] [Related]
24. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions.
Ansorge S; Bank U; Heimburg A; Helmuth M; Koch G; Tadje J; Lendeckel U; Wolke C; Neubert K; Faust J; Fuchs P; Reinhold D; Thielitz A; Täger M
Clin Chem Lab Med; 2009; 47(3):253-61. PubMed ID: 19327105
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Mulvihill EE; Drucker DJ
Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
[TBL] [Abstract][Full Text] [Related]
26. Biological function of dipeptidyl peptidase-4 on type 2 diabetes patients and diabetic mice.
Qiao J; Li L; Ma Y; Shi R; Teng M
Curr Res Transl Med; 2019 Aug; 67(3):89-92. PubMed ID: 30591375
[TBL] [Abstract][Full Text] [Related]
27. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Thompson MA; Ohnuma K; Abe M; Morimoto C; Dang NH
Mini Rev Med Chem; 2007 Mar; 7(3):253-73. PubMed ID: 17346218
[TBL] [Abstract][Full Text] [Related]
28. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
[TBL] [Abstract][Full Text] [Related]
29. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Pinheiro MM; Stoppa CL; Valduga CJ; Okuyama CE; Gorjão R; Pereira RM; Diniz SN
Eur J Pharm Sci; 2017 Mar; 100():17-24. PubMed ID: 28065853
[TBL] [Abstract][Full Text] [Related]
30. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis.
Tasic T; Bäumer W; Schmiedl A; Schwichtenhövel F; Pabst R; Raap U; von Hörsten S; Stephan M
Clin Exp Allergy; 2011 Aug; 41(8):1098-107. PubMed ID: 21672052
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.
Okada J; Yamada E; Niijima Y; Okada S; Yamada M
J Health Popul Nutr; 2019 Nov; 38(1):33. PubMed ID: 31727181
[TBL] [Abstract][Full Text] [Related]
33. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
34. The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism.
Yang Q; Fu B; Luo D; Wang H; Cao H; Chen X; Tian L; Yu X
Front Endocrinol (Lausanne); 2022; 13():856954. PubMed ID: 35586625
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase in autoimmune pathophysiology.
Ohnuma K; Hosono O; Dang NH; Morimoto C
Adv Clin Chem; 2011; 53():51-84. PubMed ID: 21404914
[TBL] [Abstract][Full Text] [Related]
36. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
Torrecillas-Baena B; Gálvez-Moreno MÁ; Quesada-Gómez JM; Dorado G; Casado-Díaz A
Stem Cell Rev Rep; 2022 Jan; 18(1):56-76. PubMed ID: 34677817
[TBL] [Abstract][Full Text] [Related]
37. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
38. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice.
Reinhold D; Goihl A; Wrenger S; Reinhold A; Kühlmann UC; Faust J; Neubert K; Thielitz A; Brocke S; Täger M; Ansorge S; Bank U
Clin Chem Lab Med; 2009; 47(3):268-74. PubMed ID: 19676138
[TBL] [Abstract][Full Text] [Related]
39. The role of Dipeptidyl Peptidase-4 in cutaneous disease.
Patel PM; Jones VA; Kridin K; Amber KT
Exp Dermatol; 2021 Mar; 30(3):304-318. PubMed ID: 33131073
[TBL] [Abstract][Full Text] [Related]
40. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.
Matheeussen V; Jungraithmayr W; De Meester I
Pharmacol Ther; 2012 Dec; 136(3):267-82. PubMed ID: 22850530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
